These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 24917231)

  • 21. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
    Kim JH; Kim SY; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia].
    Lü LX; Guo SQ; Chen W; Li Q; Cheng J; Guo JH
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1251-4. PubMed ID: 15567770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
    Maneesakorn S; Robson D; Gournay K; Gray R
    J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
    Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J
    J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
    Homer D; Nightingale P; Jobanputra P
    Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics?
    Castberg I; Westin AA; Spigset O
    J Clin Psychopharmacol; 2009 Oct; 29(5):415-20. PubMed ID: 19745639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study.
    Dursun SM; Szemis A; Andrews H; Whitaker P; Reveley MA
    J Psychiatry Neurosci; 2000 Sep; 25(4):347-52. PubMed ID: 11022399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of clozapine on medication use in a state hospital.
    Schalk DC; Wilson WH
    Hosp Pharm; 1993 Jul; 28(7):647-53. PubMed ID: 10127299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug compliance and health locus of control in schizophrenia].
    Combes C; Feral F
    Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit.
    Castberg I; Spigset O
    Ther Drug Monit; 2008 Oct; 30(5):597-603. PubMed ID: 18708990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wireless, noninvasive therapeutic drug monitoring system for saliva measurement toward medication management of schizophrenia.
    Yan Z; Shi Z; Wu Y; Lv J; Deng P; Liu G; An Z; Che Z; Lu Y; Shan J; Liu Q
    Biosens Bioelectron; 2023 Aug; 234():115363. PubMed ID: 37146537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining medication adherence in individual patients.
    Morrison A; Stauffer ME; Kaufman AS
    Patient Prefer Adherence; 2015; 9():893-7. PubMed ID: 26170639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review.
    Skokou M; Karavia EA; Drakou Z; Konstantinopoulou V; Kavakioti CA; Gourzis P; Kypreos KE; Andreopoulou O
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical use of plasma clozapine levels in a maximum security setting.
    Bennett DM; Bremner M; Gray C
    Int J Psychiatry Clin Pract; 2008; 12(3):228-34. PubMed ID: 24931662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations.
    Mayerova M; Ustohal L; Jarkovsky J; Pivnicka J; Kasparek T; Ceskova E
    Neuropsychiatr Dis Treat; 2018; 14():1535-1543. PubMed ID: 29950838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive drug adherence monitoring of antipsychotic patients via finger sweat testing.
    Longman K; Frampas C; Lewis H; Costa C; Nilforooshan R; Chambers M; Bailey M
    Front Chem; 2023; 11():1245089. PubMed ID: 37720721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a Novel Strategy for Critical Values Communication for the Management of Patients Treated with Clozapine.
    Cano-Corres R; Acebillo S; Barreda FC; Palao DJ; Berlanga-Escalera E
    EJIFCC; 2021 Dec; 32(4):458-466. PubMed ID: 35046764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of a three-dimensional model of cardiovascular disease and deployment of a new method of fostering patient adherence to instruction.
    Nakano M; Shirotake S
    Patient Prefer Adherence; 2013; 7():579-87. PubMed ID: 23836964
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.